GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Total Stockholders Equity

Qualis Innovations (Qualis Innovations) Total Stockholders Equity : $0.06 Mil (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations Total Stockholders Equity?

Qualis Innovations's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $0.06 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Qualis Innovations's Book Value per Share for the quarter that ended in Mar. 2024 was $0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Qualis Innovations's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.15.

Qualis Innovations Total Stockholders Equity Historical Data

The historical data trend for Qualis Innovations's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualis Innovations Total Stockholders Equity Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only -0.20 5.28 0.77 0.22 -0.52

Qualis Innovations Quarterly Data
Oct10 Jan11 Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.13 0.10 -0.52 0.06

Qualis Innovations  (OTCPK:QLIS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Qualis Innovations's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.061-0)/20.44
=0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Qualis Innovations's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.009 + 0) / 0.061
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qualis Innovations Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualis Innovations (Qualis Innovations) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Total Stockholders Equity
Comparable Companies
VYCO TIVC DYNT BBLG NAOV VTAK INBS NXL THMO ESMC ABT SYK MDT BSX SZSE:300760 DXCM EW ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Website
https://www.qualisinnovations.com
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751